aβ

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Gantenerumab (R-1450) is a humanized antibody targeting amyloid-β (Aβ), used in studies of Alzheimer's disease.

Trontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.

Ponezumab (PF-04360365), a humanized anti-amyloid IgG2 monoclonal antibody, effectively lowers Aβ levels in the central nervous system and enhances learning and memory performance in mouse models. It holds potential for Alzheimer's disease research [1].

MEDI-1814 is a fully human IgG1 antibody targeting the C-terminus of Aβ42. It binds to and eliminates circulating Aβ peptides, thereby preventing their aggregation into toxic oligomers. MEDI-1814 is applicable in Alzheimer's disease research. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Remternetug is a humanized IgG1-kappa monoclonal antibody that targets the N3pGlu peptide of the amyloid beta A4 precursor protein (APP) Aβ42. It specifically binds to the pyroglutamate-modified form of Aβ, which is implicated in the aggregation of amyloid plaques [1].

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a pyroglutamate amyloid beta (Aβ) epitope at the N-terminus, showing potential for early Alzheimer's disease research [1] [2].

Crenezumab (MABT 5102A) is a fully humanized anti-amyloid-beta antibody that binds to multiple forms of amyloid-beta (Aβ) for the study of Alzheimer's disease.